Bharat Biotech forays into CRDMO space with new cell & gene therapies arm Nucelion Therapeutics

HYDERABAD: Vaccine maker Bharat Biotech is foraying into the contract research development and manufacturing organisation (CDRMO) space with the setting up of a new wholly-owned subsidiary, Nucelion Therapeutics Pvt Ltd, that is focused on cell and gene therapies (CGT).Announcing its entry into this high growth CRDMO segment, Bharat Biotech said the new entity will support…

Read More

Will scrap Adani power deal if graft is proved: Bangladesh

DHAKA: Bangladesh will not hesitate to cancel a 2017 power contract with India’s Adani group if any irregularities or corruption are proven, said the Muhammad Yunus-led interim government, referring to an interim report that claimed “massive governance failure” and “massive corruption” across the energy sector.The report was submitted by the national review committee, established to…

Read More

OpenAI-Amazon cloud deal: OpenAI seals $38 billion deal with Amazon for AI computing power; Microsoft exclusivity ends

OpenAI has signed a $38 billion agreement with Amazon to run its artificial intelligence systems on Amazon Web Services (AWS), gaining access to “hundreds of thousands” of Nvidia’s AI chips through the deal announced Monday, AP reported.The partnership comes just days after OpenAI revised its arrangement with longtime backer Microsoft, which will no longer remain…

Read More

Profit paradox: What’s distorting IPO valuations? Zerodha’s Nithin Kamath shares striking insights

Nithin Kamath (File photo) For anyone investing in IPOs or tracking startup stocks, Zerodha co-founder Nithin Kamath has offered a striking explanation for why many venture-backed firms prefer losses over profits — and how India’s tax structure may be quietly driving that behaviour.In a detailed post on X, Kamath pointed out that taking money out…

Read More

US markets today: Nvidia and AI stocks lift Wall Street even as most shares decline; Dow dips, S&P 500 nears record high

Wall Street traded mixed on Monday, with major technology stocks once again steering the market higher even as most other sectors struggled. The S&P 500 added 0.4% in early trading, inching close to its record high set last week. The tech-heavy Nasdaq composite climbed 0.9%, while the Dow Jones Industrial Average slipped 34 points, or…

Read More

Consumer healthcare mega merger: Kimberly-Clark to acquire Tylenol maker Kenvue in $48.7 billion cash and stock deal; $1.9 billion cost savings targeted post-merger

Kimberly-Clark is set to acquire Tylenol maker Kenvue in a cash-and-stock transaction valued at approximately $48.7 billion, creating one of the world’s largest consumer health goods companies, AP reported.Under the terms of the agreement, Kenvue shareholders will receive $3.50 per share in cash and 0.14625 Kimberly-Clark shares for each Kenvue share held at closing. Based…

Read More